<p>Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - 獲取免費報告) 的股價在週一的午盤交易中達到了新的 52 周高點。該公司的股價最高達到 21.49 美元，最後交易價格為 21.4850 美元，成交量為 66811 股。該股票此前收盤價為 21.47 美元。</p>
<h2>分析師評級調整</h2>
<p>多家研究公司對 DAWN 發佈了報告。TD Cowen 在 3 月 6 日的報告中將 Day One Biopharmaceuticals 的股票評級從 “買入” 下調至 “持有”。Zacks Research 在 2 月 25 日的報告中將 Day One Biopharmaceuticals 的股票評級從 “強力買入” 下調至 “持有”。Oppenheimer 在 3 月 6 日的報告中重申了對 Day One Biopharmaceuticals 的 “市場表現” 評級。Needham &amp; Company LLC 在 3 月 6 日的報告中將 Day One Biopharmaceuticals 的股票評級從 “買入” 下調至 “持有”。最後，HC Wainwright 在 3 月 10 日的報告中重申了 “中性” 評級，並將 Day One Biopharmaceuticals 的目標價設定為 21.50 美元（下調自 22.00 美元）。一位投資分析師對該股票給予了買入評級，八位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “持有”，共識目標價為 23.29 美元。</p>
<p><strong>查看我們對 DAWN 的最新分析</strong></p>
<h2>Day One Biopharmaceuticals 股票表現</h2>
<p>該股票的 50 日簡單移動平均線為 17.61 美元，200 日簡單移動平均線為 12.08 美元。該公司的市值為 22.2 億美元，市盈率為-20.86，貝塔值為-1.74。</p>
<p>Day One Biopharmaceuticals (NASDAQ:DAWN - 獲取免費報告) 最近在 2 月 24 日公佈了季度財報。該公司報告的每股收益為-0.21 美元，低於分析師一致預期的-0.17 美元，差距為 0.04 美元。該公司在本季度的收入為 5372 萬美元，而分析師預期為 4981 萬美元。Day One Biopharmaceuticals 的淨利潤率為-67.85%，股本回報率為-23.43%。分析師預計，Day One Biopharmaceuticals, Inc.在當前年度的每股收益將為-0.72 美元。</p>
<h2>Day One Biopharmaceuticals 的內部交易</h2>
<p>在相關消息中，內部人士 Lauren Merendino 在 2 月 17 日的交易中出售了 5814 股該股票。股票的平均售價為 11.60 美元，總價值為 67442.40 美元。交易後，該內部人士直接持有 60157 股公司股票，價值為 697821.20 美元。這筆交易代表其持股比例減少了 8.81%。該交易已在 SEC 的備案中披露，相關信息可通過 SEC 網站獲取。此外，內部人士 Adam Dubow 在 2 月 17 日的交易中出售了 6395 股該股票。股票的平均售價為 11.60 美元，總交易額為 74182.00 美元。交易完成後，該內部人士直接持有 72694 股公司股票，價值為 843250.40 美元。這筆交易代表其持股比例減少了 8.09%。該銷售的 SEC 備案提供了更多信息。在過去三個月中，內部人士共出售了 36461 股公司股票，價值為 422948 美元。內部人士持有公司股票的比例為 6.20%。</p>
<h2>Day One Biopharmaceuticals 的機構交易</h2>
<p>大型投資者最近買入和賣出了該公司的股票。Federated Hermes Inc.在第三季度收購了 Day One Biopharmaceuticals 的新股份，價值 39000 美元。Mirae Asset Global Investments Co. Ltd.在第四季度將其在 Day One Biopharmaceuticals 的股份增加了 26.0%。Mirae Asset Global Investments Co. Ltd.現在擁有 4989 股該公司的股票，價值 46000 美元，此前在該期間內又購買了 1029 股。Quarry LP 在第三季度收購了 Day One Biopharmaceuticals 的新股份，價值 49000 美元。Prudential Financial Inc.在第二季度收購了 Day One Biopharmaceuticals 的新股份，價值 69000 美元。最後，CWM LLC 在第四季度將其在 Day One Biopharmaceuticals 的股份增加了 32.4%。CWM LLC 現在擁有 8373 股該公司的股票，價值 78000 美元，此前在該期間內又購買了 2051 股。機構投資者和對沖基金持有該公司 87.95% 的股票。</p>
<h2>關於 Day One Biopharmaceuticals</h2>
<p>(獲取免費報告)</p>
<p>Day One Biopharmaceuticals, Inc. NASDAQ: DAWN 是一家臨牀階段的生物製藥公司，專注於針對腫瘤的靶向治療的發現和開發。該公司採用精準醫療的方法，利用生物標誌物驅動的策略來識別最有可能對其研究化合物產生反應的患者羣體。通過集中於經過充分驗證的癌症分子驅動因素，Day One 旨在提供具有重要臨牀益處的首創或最佳治療。</p>
<p>該公司的產品管線包括多個處於不同開發階段的小分子候選藥物。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Day One Biopharmaceuticals</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Day One Biopharmaceuticals 嗎？</h2>
<p>在你考慮投資 Day One Biopharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Day One Biopharmaceuticals 並不在名單上。</p>
<p>雖然 Day One Biopharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

DAWN

<p>Day One Biopharmaceuticals（納斯達克代碼：DAWN）在交易中達到了新的 52 周高點 21.49 美元。該股票收盤價為 21.4850 美元，成交量為 66,811 股。分析師已將該股票評級從 “買入” 下調至 “持有”，共識目標價為 23.29 美元。公司報告的季度每股收益為（0.21 美元），未達到預期，但收入為 5372 萬美元，超出預期。內部人士最近出售了股票，機構投資者持有該股票的 87.95%。Day One 專注於靶向腫瘤治療，並有多個候選藥物在開發中</p>

<p>Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $21.49 and last traded at $21.4850, with a volume of 66811 shares. The stock had previously closed at $21.47.</p>
<div class="lb-trans"><p>Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - 獲取免費報告) 的股價在週一的午盤交易中達到了新的 52 周高點。該公司的股價最高達到 21.49 美元，最後交易價格為 21.4850 美元，成交量為 66811 股。該股票此前收盤價為 21.47 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>A number of research firms have issued reports on DAWN. TD Cowen lowered shares of Day One Biopharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Friday, March 6th. Zacks Research lowered shares of Day One Biopharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Wednesday, February 25th. Oppenheimer reiterated a &#34;market perform&#34; rating on shares of Day One Biopharmaceuticals in a report on Friday, March 6th. Needham &amp; Company LLC lowered shares of Day One Biopharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Friday, March 6th. Finally, HC Wainwright reiterated a &#34;neutral&#34; rating and set a $21.50 target price (down from $22.00) on shares of Day One Biopharmaceuticals in a report on Tuesday, March 10th. One investment analyst has rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of &#34;Hold&#34; and a consensus target price of $23.29.</p>
<div class="lb-trans"><p>多家研究公司對 DAWN 發佈了報告。TD Cowen 在 3 月 6 日的報告中將 Day One Biopharmaceuticals 的股票評級從 “買入” 下調至 “持有”。Zacks Research 在 2 月 25 日的報告中將 Day One Biopharmaceuticals 的股票評級從 “強力買入” 下調至 “持有”。Oppenheimer 在 3 月 6 日的報告中重申了對 Day One Biopharmaceuticals 的 “市場表現” 評級。Needham &amp; Company LLC 在 3 月 6 日的報告中將 Day One Biopharmaceuticals 的股票評級從 “買入” 下調至 “持有”。最後，HC Wainwright 在 3 月 10 日的報告中重申了 “中性” 評級，並將 Day One Biopharmaceuticals 的目標價設定為 21.50 美元（下調自 22.00 美元）。一位投資分析師對該股票給予了買入評級，八位分析師給予了持有評級，一位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “持有”，共識目標價為 23.29 美元。</p>
</div><p><strong>View Our Latest Analysis on DAWN</strong></p>
<div class="lb-trans"><p><strong>查看我們對 DAWN 的最新分析</strong></p>
</div><h2>Day One Biopharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Day One Biopharmaceuticals 股票表現</h2>
</div><p>The stock's 50-day simple moving average is $17.61 and its 200 day simple moving average is $12.08. The company has a market capitalization of $2.22 billion, a PE ratio of -20.86 and a beta of -1.74.</p>
<div class="lb-trans"><p>該股票的 50 日簡單移動平均線為 17.61 美元，200 日簡單移動平均線為 12.08 美元。該公司的市值為 22.2 億美元，市盈率為-20.86，貝塔值為-1.74。</p>
</div><p>Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.04). The firm had revenue of $53.72 million during the quarter, compared to analysts' expectations of $49.81 million. Day One Biopharmaceuticals had a negative net margin of 67.85% and a negative return on equity of 23.43%. On average, analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current year.</p>
<div class="lb-trans"><p>Day One Biopharmaceuticals (NASDAQ:DAWN - 獲取免費報告) 最近在 2 月 24 日公佈了季度財報。該公司報告的每股收益為-0.21 美元，低於分析師一致預期的-0.17 美元，差距為 0.04 美元。該公司在本季度的收入為 5372 萬美元，而分析師預期為 4981 萬美元。Day One Biopharmaceuticals 的淨利潤率為-67.85%，股本回報率為-23.43%。分析師預計，Day One Biopharmaceuticals, Inc.在當前年度的每股收益將為-0.72 美元。</p>
</div><h2>Insider Transactions at Day One Biopharmaceuticals</h2>
<div class="lb-trans"><h2>Day One Biopharmaceuticals 的內部交易</h2>
</div><p>In related news, insider Lauren Merendino sold 5,814 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $67,442.40. Following the transaction, the insider directly owned 60,157 shares of the company's stock, valued at $697,821.20. This trade represents a 8.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Adam Dubow sold 6,395 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $74,182.00. Following the completion of the transaction, the insider directly owned 72,694 shares in the company, valued at $843,250.40. This trade represents a 8.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 36,461 shares of company stock worth $422,948. Insiders own 6.20% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，內部人士 Lauren Merendino 在 2 月 17 日的交易中出售了 5814 股該股票。股票的平均售價為 11.60 美元，總價值為 67442.40 美元。交易後，該內部人士直接持有 60157 股公司股票，價值為 697821.20 美元。這筆交易代表其持股比例減少了 8.81%。該交易已在 SEC 的備案中披露，相關信息可通過 SEC 網站獲取。此外，內部人士 Adam Dubow 在 2 月 17 日的交易中出售了 6395 股該股票。股票的平均售價為 11.60 美元，總交易額為 74182.00 美元。交易完成後，該內部人士直接持有 72694 股公司股票，價值為 843250.40 美元。這筆交易代表其持股比例減少了 8.09%。該銷售的 SEC 備案提供了更多信息。在過去三個月中，內部人士共出售了 36461 股公司股票，價值為 422948 美元。內部人士持有公司股票的比例為 6.20%。</p>
</div><h2>Institutional Trading of Day One Biopharmaceuticals</h2>
<div class="lb-trans"><h2>Day One Biopharmaceuticals 的機構交易</h2>
</div><p>Large investors have recently bought and sold shares of the business. Federated Hermes Inc. acquired a new stake in Day One Biopharmaceuticals during the 3rd quarter worth $39,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Day One Biopharmaceuticals by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company's stock worth $46,000 after purchasing an additional 1,029 shares during the period. Quarry LP acquired a new stake in Day One Biopharmaceuticals during the 3rd quarter worth $49,000. Prudential Financial Inc. acquired a new stake in Day One Biopharmaceuticals during the 2nd quarter worth $69,000. Finally, CWM LLC boosted its stake in Day One Biopharmaceuticals by 32.4% during the 4th quarter. CWM LLC now owns 8,373 shares of the company's stock worth $78,000 after purchasing an additional 2,051 shares during the period. Institutional investors and hedge funds own 87.95% of the company's stock.</p>
<div class="lb-trans"><p>大型投資者最近買入和賣出了該公司的股票。Federated Hermes Inc.在第三季度收購了 Day One Biopharmaceuticals 的新股份，價值 39000 美元。Mirae Asset Global Investments Co. Ltd.在第四季度將其在 Day One Biopharmaceuticals 的股份增加了 26.0%。Mirae Asset Global Investments Co. Ltd.現在擁有 4989 股該公司的股票，價值 46000 美元，此前在該期間內又購買了 1029 股。Quarry LP 在第三季度收購了 Day One Biopharmaceuticals 的新股份，價值 49000 美元。Prudential Financial Inc.在第二季度收購了 Day One Biopharmaceuticals 的新股份，價值 69000 美元。最後，CWM LLC 在第四季度將其在 Day One Biopharmaceuticals 的股份增加了 32.4%。CWM LLC 現在擁有 8373 股該公司的股票，價值 78000 美元，此前在該期間內又購買了 2051 股。機構投資者和對沖基金持有該公司 87.95% 的股票。</p>
</div><h2>About Day One Biopharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Day One Biopharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Day One Biopharmaceuticals, Inc NASDAQ: DAWN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.</p>
<div class="lb-trans"><p>Day One Biopharmaceuticals, Inc. NASDAQ: DAWN 是一家臨牀階段的生物製藥公司，專注於針對腫瘤的靶向治療的發現和開發。該公司採用精準醫療的方法，利用生物標誌物驅動的策略來識別最有可能對其研究化合物產生反應的患者羣體。通過集中於經過充分驗證的癌症分子驅動因素，Day One 旨在提供具有重要臨牀益處的首創或最佳治療。</p>
</div><p>The company's pipeline includes several small-molecule candidates in various stages of development.</p>
<div class="lb-trans"><p>該公司的產品管線包括多個處於不同開發階段的小分子候選藥物。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Day One Biopharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Day One Biopharmaceuticals</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Day One Biopharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Day One Biopharmaceuticals 嗎？</h2>
</div><p>Before you consider Day One Biopharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Day One Biopharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每日推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Day One Biopharmaceuticals 並不在名單上。</p>
</div><p>While Day One Biopharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Day One Biopharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Day One Biopharmaceuticals (NASDAQ:DAWN) Hits New 1-Year High  - What's Next?

Market Beat

Day One Biopharmaceuticals

Day One Biopharmaceuticals（NASDAQ:DAWN）創下 1 年新高 - 接下來會如何發展？